Gary, DCVax is being tested in the maintenance setting.
Remember Stimuvax? That too was tested in the maintenance setting.
Like DCVax, Stimuvax trial patients were randomized after completion of their chemorad. Remember the Stimuvax START trial? All patients randomized had to be non-progressing. Don't you remember looking at this, in depth? Remember all those arguments with people citing NSCLC Trials w/o consideration for the fact the those trials didn't screen for progression after chemorad?
This is a very similar situation.
Nothing wrong with that approach, it's done in many indications. What's wrong is comparing apples to oranges.
Market Data 
Markets 
AI
